Cellyan Biotechnology Co., Ltd - Class A Ordinary Shares (HKPD)
Industrials › Wholesale-Drugs, Proprietaries & Druggists' Sundries
Price History
Feb 9, 2026 — Mar 29, 2026Investment Snapshot
- P/B of 1.45 — trading near book value
- Piotroski F-Score 4/9 — moderate financial health
- Loss-making — negative ROE of -0.5%
- Revenue growing at 22% annually
Cellyan Biotechnology Co., Ltd - Class A Ordinary Shares (HKPD) is a Industrials company operating in Wholesale-Drugs, Proprietaries & Druggists' Sundries, listed on the NASDAQ , with a market capitalisation of $7 million . Key value metrics: P/B ratio 1.45, Piotroski F-Score 4 out of 9 (moderate financial health) .
Value Score
Key Metrics
Cellyan Biotechnology Co., Ltd - Class A Ordinary Shares — Fundamental Analysis Summary
On financial health, HKPD shows a moderate Piotroski F-Score of 4/9, and negative return on equity of -0.5% (sector average: 5.5%), and manageable leverage with a debt-to-equity ratio of 0.33.
StockPik's composite Value Score for HKPD is 63/100 — an above-average value rating. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
HKPD reports a thin gross margin of 11.9% (sector average: 24.7%) and a negative operating margin of -11.2%.
HKPD shows revenue growing at 22% year-over-year, with earnings declining at 102%.